US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Moderna says norovirus vaccine trial on FDA clinical hold
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Moderna Scales Down Manufacturing
The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.
Moderna’s Shot Sales, Canceled Contract Lead to Another Loss
The company’s earnings update initially discouraged investors, who traded the stock down as much as 8.4% when the market opened Friday. The shares later rallied, gaining as much as 6.2%, amid broader ...
Hosted on MSN23h
Will Moderna's Retained 2025 Outlook Bolster Its Depressed Shares?
Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday as sales topped Wall Street's projections, but on steep losses.